ARCHIVES

IVAX Agreement With Rival BMS Appears To Buttress BMS control of Paclitaxel

This article is from The Cancer Letter archive.

Vol. 25 No. 45 | November 26, 1999

Download PDF Visit The Full Archive

Related Articles

NCI To Boost Investigator-Initiated Grants Using 5.7% Increase, Cuts In Contracts

February 9, 1996

EPO Controversy: ODAC To Review EPO Agents in May; SEC Probes Amgen’s Delay in Study Disclosure.

March 2, 2007

NCI blocked groups from phase III Iressa studies.

April 30, 2004

Tamoxifen Offers Long-Term Benefits For Prevention

March 30, 2007

Albino African Skin Cancer Study To Be Reevaluated

April 11, 1980

Fermilab Treats 1,000th Patient

August 7, 1981